Open Actively Recruiting

Study of SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

About

Brief Summary

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
Male
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
24-5009
Category
Prostate Cancer
Contact
Sandy Hernandez
Location
  • UCLA Encino
  • UCLA Irvine
  • UCLA Marina del Rey
  • UCLA Pasadena
  • UCLA Porter Ranch
  • UCLA Santa Clarita
  • UCLA Santa Monica
  • UCLA Ventura
  • UCLA Westwood
For Providers
NCT No.
NCT06228053
For detailed technical eligibility, visit ClinicalTrials.gov.